Drug

Olpasiran

In clinical development

ClassLPA mRNA rnai inhibitorEmerging researchLate-stage development

Also known as ALL-P-AMBO-5'-O-((25S,30S)-39-((2-ACETAMIDO-2-DEOXY-.BETA.-D-GALACTOPYRANOSYL)OXY)-25,30-BIS((2-(2-((2-ACETAMIDO-2-DEOXY-.BETA.-D-GALACTOPYRANOSYL)OXY)ETHOXY)ETHYL)CARBAMOYL)-1,23,28,33-TETRAOXO-1-SULFANYL-2,5,8,11,14,17,20,37-OCTAOXA-24,29,34-TRIAZA-1.L.

RxNorm2686350 ChEMBLCHEMBL4650413UNII8M4GC1EOB4

Research papers

Active clinical trials

Protein targets

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a)

Clinical trial2026-07-10Results expected Q4 2031 · ClinicalTrials.gov

A Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Safety, Tolerability, and Effect of Olpasiran on Coronary Artery Plaque Burden Assessed by Coronary Computed Tomography Angiography in Participants With Stable Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a)

Clinical trial2026-04-16Results expected Q2 2028 · ClinicalTrials.gov

A Double-blind, Randomized, Placebo-controlled Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of Olpasiran (AMG 890) in Subjects With Elevated Lipoprotein(a)

Clinical trial2026-03-31Results posted · ClinicalTrials.gov

A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a)

Clinical trial2026-02-27Results expected Q1 2028 · ClinicalTrials.gov

An Open-label, Single-dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Olpasiran in Chinese Subjects With Elevated Serum Lipoprotein(a)

Clinical trial2025-02-10Results posted · ClinicalTrials.gov

A Randomized, Placebo- and Positive-controlled, Crossover Study to Assess the Effect of Olpasiran (AMG 890) on QT/QTc Intervals in Healthy Subjects

Clinical trial2024-12-11Completed · ClinicalTrials.gov

A Phase I, Open-label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Subjects With Normal Renal Function and Subjects With Various Degrees of Renal Impairment

Clinical trial2023-12-19Completed · ClinicalTrials.gov

A Phase I, Open-label Single Dose Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Subjects With Various Degrees of Hepatic Impairment

Clinical trial2023-05-31Completed · ClinicalTrials.gov

Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease.

Research2022-11-06The New England journal of medicine

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Olpasiran

Aliases & brands

ALL-P-AMBO-5'-O-((25S,30S)-39-((2-ACETAMIDO-2-DEOXY-.BETA.-D-GALACTOPYRANOSYL)OXY)-25,30-BIS((2-(2-((2-ACETAMIDO-2-DEOXY-.BETA.-D-GALACTOPYRANOSYL)OXY)ETHOXY)ETHYL)CARBAMOYL)-1,23,28,33-TETRAOXO-1-SULFANYL-2,5,8,11,14,17,20,37-OCTAOXA-24,29,34-TRIAZA-1.L

RxNorm CUI

2686350

ChEMBL ID

CHEMBL4650413

UNII

8M4GC1EOB4

Primary mechanism

LPA mRNA rnai inhibitor

Pharmacology & targets

1 target

Known molecular targets and mechanisms supported by curated pharmacology databases.

ENSG00000198670

RNAI INHIBITORLPA mRNA rnai inhibitor

Clinical trials

8 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme

CLINICALTRIALS.GOV · LIVE REGISTRY

registered trials across all phases

LATEST COMPLETION 2024

Active studies

Recruiting

Late-stage (III+)

Completed

PHASE DISTRIBUTIONn = 8

Phase 14Phase 21Phase 33

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a)

RecruitingPH IIIKey trialAmgenn=11,0002031

RecruitingPH IIIAmgenn=4062028

Active, not recruitingPH IIIKey trialAmgenn=7,2972028

Recent completions

Trials that read out recently, adding to the completed evidence base.

A Randomized, Placebo- and Positive-controlled, Crossover Study to Assess the Effect of Olpasiran (AMG 890) on QT/QTc Intervals in Healthy Subjects

CompletedPH IAmgenn=322024

CompletedPH IAmgenn=332023

A Phase I, Open-label Single Dose Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Subjects With Various Degrees of Hepatic Impairment

CompletedPH IAmgenn=252023

A Double-blind, Randomized, Placebo-controlled Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of Olpasiran (AMG 890) in Subjects With Elevated Lipoprotein(a)

CompletedPH IIAmgenn=2812022

An Open-label, Single-dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Olpasiran in Chinese Subjects With Elevated Serum Lipoprotein(a)

CompletedPH IAmgenn=242022

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Most influential

Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease.

The New England journal of medicine · 2022 · 405 cites

Related drugs

1 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Ezetimibe

Studied across 3 of the same disease areas as Olpasiran in the shared literature.

3 shared diseases1 shared paper

References & data sources

RxNorm (U.S. National Library of Medicine) — drug identity
ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
Europe PMC — research literature
ClinicalTrials.gov — clinical trials